Press releases

10
Dec 2024
19:50 E.S.T.

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

Read more
5
Nov 2024
21:30 E.S.T.

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Read more
4
Nov 2024
21:30 E.S.T.

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

Read more
30
Oct 2024
20:30 E.S.T.

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Read more
22
Oct 2024
06:00 E.S.T.

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

Read more
3
Sep 2024
15:05 E.S.T.

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Read more
26
Aug 2024
14:35 E.S.T.

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

Read more
7
Aug 2024
06:00 E.S.T.

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Read more
6
Aug 2024
20:30 E.S.T.

Cellectis Provides Financial Results for the Second Quarter 2024

Read more
1
Aug 2024
20:30 E.S.T.

FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US